Press release
Illumina launches pilot proteomics program with UK Biobank and biopharma collaborators to analyze 50,000 samples
Study will generate a key reference data set with Illumina Protein Prep solution SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a
About this update from Illumina, Inc.
[{"type":"text","content":"Study will generate a key reference data set with Illumina Protein Prep solution\nSAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson & Johnson, and Novartis. The pilot program is based on Illumina's upcoming proteomics assay, Illumina Protein Prep™, powered by SOMAmer® technology, a next-generation sequencing (NGS) based solution that will help scale access to proteomic insights.\n\nProteomics enables the observation of direct cellular function to improve understanding of the role of proteins in health and disease, and facilitates biomarker discovery for conditions such as cancer and cardiovascular disease. Researchers use protein quantitative trait loci (pQTLs), which are emerging as a vital proteogenomic tool for drug discovery, linking genetic variation with protein expression data and disease or other phenotypes. With the advent of high-throughput proteomics methods such as Illumina Protein Prep, the discovery of new pQTLs is now more accessible.\n\"UK Biobank data has set the standard as a reference dataset for the omics community, and we're excited to collaborate across the health care industry in this pilot study as we prepare to launch Illumina Protein Prep,\" said Steve Barnard, PhD, chief technology officer of Illumina. \"We believe the pilot program will generate a new collection of high-quality, NGS-based proteomics data for the research community and pharma partners to advance biological insights.\"\nUK Biobank will provide 50,000 samples from the same study participants who are included in the UK Biobank Pharma Proteomics Project, a separate research collaboration between the UK Biobank and 14 biopharmaceutical companies. deCODE Genetics will process the samples using the Illumina Protein Prep solution and NovaSeq™ X Plus system, and run analysis using the DRAGEN Protein Quantification pipeline. The first 30,000 samples are funded through coinvestment from Illumina, deCODE Genetics, and Standard BioTools, Inc., with automation partner support from Tecan. The data generated from these first 30,000 samples will be made available by UK Biobank immediately to the scientific resear...